The high quality of the scientific expertise at Vivolux has made us a valued partner in many development projects. At present, the company is focusing on areas of research where this expertise will help to establish a basis for scientific advances or the creation of substances capable of seeking out specific disease-causing agents.
The following are some of the collaborative ventures in which Vivolux is involved:
The collaboration with Professor Stig Linder at the Karolinska Institute has been pivotal in establishing the Vivolux project portfolio. The mechanistic investigations at these sites have led to the identification of two novel therapeutic targets and identified agents that act specifically on these targets. This work has laid the foundation for Vivolux's two INDs, which are now at the clinical phase in the Vivolux portfolio. This collaboration has resulted in several publications and patents related to the mechanism in targeting quiescent cancer cells (VLX600 program) and upstream proteasome inhibition (VLX1570 program). Stig Linder, CSO at Vivolux and a Board member, is Professor of Cancer Pharmacology at Karolinska Institute.
The collaboration with Linköping University started as a Multi Drug Resistance (MDR) inhibitor project in collaboration with Professor Curt Peterson. Now the cooperation is related to the mechanism of action investigation of Vivolux's first-in-class compounds. The work is supervised by Stig Linder as Professor of Pharmacology at Linköping University.
Vivolux has long-standing collaboration with Uppsala University. Based on a unique preclinical development platform, Drug Activity Profiling System (DAPS), which reflects the cancer phenotype ex vivo, Vivolux has optimized and verified highly promising anti-cancer properties of molecules from different substance classes and identified their molecular mechanism of action. The collaboration has been supervised by Professor Rolf Larsson (Clinical Pharmacology), and Professor Peter Nygren (Oncology) and Associate Professor Mårten Fryknäs together with Joachim Gullbo, and has resulted in several publications. Joachim Gullbo MD PhD, Medical Adviser to Vivolux, is Associate Professor of Experimental Clinical Pharmacology at Uppsala University.
Dana-Farber Cancer Institute, Boston MA, USA
Mayo Clinic, Rochester, Scottsdale, Jacksonville, USA
Memorial Sloan Kettering Cancer Center, New York, USA
Rush University Medical Center, Chicago, USA
Sarah Cannon Research Institute, Nashville, USA